Form 8-K - Current report:
SEC Accession No. 0001650664-25-000020
Filing Date
2025-03-05
Accepted
2025-03-05 16:11:26
Documents
16
Period of Report
2025-03-05
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K edit-20250305.htm   iXBRL 8-K 27368
2 EX-99.1 editasmedicinepressrelease.htm EX-99.1 81858
7 GRAPHIC image_0.jpg GRAPHIC 61309
  Complete submission text file 0001650664-25-000020.txt   340041

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT edit-20250305.xsd EX-101.SCH 2129
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT edit-20250305_def.xml EX-101.DEF 2931
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT edit-20250305_lab.xml EX-101.LAB 23733
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT edit-20250305_pre.xml EX-101.PRE 14223
18 EXTRACTED XBRL INSTANCE DOCUMENT edit-20250305_htm.xml XML 3199
Mailing Address 11 HURLEY ST. CAMBRIDGE MA 02141
Business Address 11 HURLEY ST. CAMBRIDGE MA 02141 617-401-9000
Editas Medicine, Inc. (Filer) CIK: 0001650664 (see all company filings)

EIN.: 464097528 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37687 | Film No.: 25711077
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)